Zentiva Advances Drug Research Through EU's Orbis Project

One of the missions that Zentiva of the Czech Republic pursues is to connect academe and the pharmaceutical industry to accelerate drug development innovation and provide better health care for patients, Deutsche Presse-Agentur (dpa) reported.

Photo Insert: Zentiva in Prague

Zentiva has resumed its scientific exchange program as part of the Orbis project, which was created within the largest EU grant programs Horizon 2020, to connect European and American universities with industrial partners at the scientific level.

Thanks to the experience gained in the health and safety of the working environment during the COVID-19 pandemic as well as to massive roll-out of vaccination programs after 1.5 years, Zentiva is reopening its laboratories to promising European scientists to boost pharmaceutical research, dpa reported.

In October, Zentiva welcomed its first of several new students who will be conducting their company research. Jernej Stukelj, who arrived in Zentiva for a three-month study stay from the University of Helsinki, will dedicate his work in Prague to test novel dissolution methods that have been developed at his home university, using real-life examples provided by Zentiva.

"The cooperation within ORBIS represents an excellent opportunity for all partners. While academic research aims to increase understanding on the fundamental levels, the industry is providing real-life examples where academic hypotheses can be tested and further developed, providing new opportunities to learn to all involved partners. This is further increasing our innovation power aimed to develop difficult to make generics and value-added medicines, meeting currently unmet needs in healthcare," stressed Pavel Sebek, Zentiva’s development director.

WEEKLY FEATURE : MVP Group Keeps Lights On During Pandemic